IDO-derived cancer vaccine scores in combo trial with Keytruda; Vir teams up with WuXi on coronavirus antibodies
→ Copenhagen-based IO Biotech said that its cancer vaccine has passed the high bar set for its interim futility analysis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
